Patents Assigned to Shire International Licensing B.V.
  • PHARMACEUTICAL COMPOSITIONS CONTAINING LANTHANUM HYDROXYCARBONATE
    Publication number: 20100092576
    Abstract: An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.
    Type: Application
    Filed: December 11, 2009
    Publication date: April 15, 2010
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Donald Hallenbeck, Simon Bates
  • COMBINATION OF A LANTHANUM COMPOUND AND BONE ENHANCING AGENT FOR THE TREATMENT OF BONE DISEASES
    Publication number: 20100015246
    Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D.
    Type: Application
    Filed: June 16, 2009
    Publication date: January 21, 2010
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Nigel D. Atherton, Michael David Gaitonde, Joseph William Totten, Peter Neil Davies, Rymond Dennis Pratt
  • Method for use of lanthanum carbonate pharmaceutical compositions
    Patent number: 7618656
    Abstract: A method for treating hyperphosphatemia using lanthanum carbonate, including analytically determining the amount of an impurity in the lanthanum carbonate sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 17, 2009
    Assignee: Shire International Licensing B.V.
    Inventors: Donald Hallenbeck, Simon Bates
  • Stabilized lanthanum carbonate compositions
    Patent number: 7381428
    Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: June 3, 2008
    Assignee: Shire International Licensing B.V.
    Inventors: Josephine Christine Ferdinando, Peter Neil Davies
  • METHOD OF USE FOR LANTHANUM CARBONATE AND LANTHANUM HYDROXYCARBONATE
    Publication number: 20080089948
    Abstract: A method for treating hyperphosphatemia using lanthanum carbonate, including analytically determining the amount of an impurity in the lanthanum carbonate sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 17, 2008
    Applicant: Shire International Licensing B.V.
    Inventors: Donald Hallenbeck, Simon Bates
  • Assay for lanthanum hydroxycarbonate
    Publication number: 20070259052
    Abstract: An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.
    Type: Application
    Filed: May 5, 2006
    Publication date: November 8, 2007
    Applicant: Shire International Licensing B.V.
    Inventors: Donald Hallenbeck, Simon Bates
  • USE OF RARE EARTH COMPOUNDS FOR THE PREVENTION OF KIDNEY STONE DISEASE
    Publication number: 20070116782
    Abstract: Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.
    Type: Application
    Filed: October 5, 2006
    Publication date: May 24, 2007
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Michael Abrams, Gary Bridger, Simon Fricker, Stefan Idzan
  • Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
    Publication number: 20070104799
    Abstract: A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.
    Type: Application
    Filed: November 9, 2005
    Publication date: May 10, 2007
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Raymond Pratt, Isobel Webster, Stephen Damment
  • Use of rare earth compounds for the prevention of kidney stone disease
    Patent number: 7192609
    Abstract: Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: March 20, 2007
    Assignee: Shire International Licensing B.V.
    Inventors: Michael J. Abrams, Gary J. Bridger, Simon P. Fricker, Stefan R. Idzan
  • Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
    Publication number: 20070048390
    Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D.
    Type: Application
    Filed: February 2, 2006
    Publication date: March 1, 2007
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Nigel Atherton, Michael Gaitonde, Joseph Totten, Peter Davies, Raymond Pratt
  • Stabilized lanthanum carbonate compositions
    Publication number: 20060121127
    Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.
    Type: Application
    Filed: November 9, 2005
    Publication date: June 8, 2006
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Josephine Ferdinando, Peter Davies